CONNECT WITH US
HealthTech

HealthTech

1 in 10 U.S. adults reported GLP-1 medication use July to August 2025

Medical Xpress logo

Published on

Add as a preferred source on Google
1 in 10 U.S. adults reported GLP-1 medication use July to August 2025

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

From July to August 2025, about one in 10 U.S. adults reported taking a glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication during the past year, according to research published in Morbidity and Mortality Weekly Report.

Samantha L. Pierce, M.P.H., from the CDC in Atlanta, and colleagues examined GLP-1 RA medication use among U.S. adults using data collected from the CDC Rapid Surveys System from July to August 2025.

In addition to the adults reporting taking a GLP-1 RA medication during the past year, about one in five GLP-1 RA users reported using a compounded version; these versions have not been reviewed by the U.S. Food and Drug Administration for safety, effectiveness or quality before marketing. About two in five GLP-1 RA users reported modification of medication use from the way it was prescribed, with barriers to prescribed use including cost and availability.

"Modifications in GLP-1 medication use reflect, in part, responses to cost- and access-related challenges," the authors write. "Future research could evaluate the implications of real-world medication use, including dose and frequency adjustments, on safety and effectiveness."

Samantha L. Pierce et al., Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025, MMWR. Morbidity and Mortality Weekly Report (2026). DOI: 10.15585/mmwr.mm7544a1



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.